whether inhaled tiotropium and ipratropium increase stroke, heart attack, and death in COPD patients

Experts are debating whether inhaled tiotropium and ipratropium increase stroke, heart attack, and death in COPD patients.

The lay press picked up on a recent meta-analysis linking tiotropium (Spiriva) and ipratropium (Atrovent, Combivent) to a higher risk of cardiovascular events.

But don't jump to conclusions. There are two sides to the story.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote